TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HBM Holdings Ltd. ( (HK:2142) ) has shared an announcement.
HBM Holdings Ltd. has announced an advancement in its global collaboration with AstraZeneca, aimed at discovering and developing next-generation biotherapeutics. The amendment to their existing agreement enhances the scope of their partnership, maintaining the original economic terms, and underscores their commitment to leveraging combined expertise in biotechnology.
The most recent analyst rating on (HK:2142) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
More about HBM Holdings Ltd.
HBM Holdings Ltd. operates in the biopharmaceutical industry, focusing on the discovery and development of innovative therapeutics. The company specializes in next-generation biotherapeutics, including antibody-drug conjugates and T cell engagers, with a market focus on leveraging advanced biotechnology for medical advancements.
Average Trading Volume: 8,103,216
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.39B
Learn more about 2142 stock on TipRanks’ Stock Analysis page.